High serum adiponectin is associated with favorable lipoprotein subclass profile in 6.4-year follow-up

European Journal of Endocrinology

Volumn 164, Issue 4, 2011, Pages 549-552

  Vanhala, Mauno ^a,e   Kumpula, Linda S ^b   Soininen, Pasi ^b,c   Kangas, Antti J ^b   Ala Korpela, Mika ^b,c   Kautiainen, Hannu ^a,d   Mäntyselkä, Pekka ^e   Saltevo, Juha ^a  

^a CENTRAL FINLAND CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Orton Hospital   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ESTROGEN THERAPY; FEMALE; FINLAND; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SEX DIFFERENCE; LONGITUDINAL STUDY; MEDICAL EXAMINATION;

ADIPONECTIN; ADULT; APOLIPOPROTEIN A-I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; TIME FACTORS;

EID: 79953169900     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-1065     Document Type: Article

References (18)

1. Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Poburska K, Fritsche A, Häring H-U & Stefan N. The relationship of plasma adiponectin with a favorable lipid profile, decreased inflammation and less ectopic fat accumulation depend on adiposity. Clinical Chemistry 2006 52 1934-1942. (doi:10.1373/clinchem.2006.067397)
2. Weiss R, Otvos JD, Flybjerg A, Miserez AR, Frystyk J, Sinnreich R & Kark JD. Adiponectin and lipoprotein particle size. Diabetes Care 2009 32 1317-1319. (doi:10.2337/dc09-0084)
3. Ng TW, Watts GF, Farvid MS, Chan DC & Barrett PH. Adipocytokines LDL metabolism. Independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics. Diabetes 2005 54 795-802. (doi:10.2337/diabetes.54.3.795)
4. Ahonen T, Kautiainen H, Keinänen-Kiukaanniemi S, Kumpusalo E & Vanhala M. Gender difference among smoking, adiponectin, and high-sensitivity C-reactive protein. American Journal of Preventive Medicine 2008 35 598-601. (doi:10.1016/j.amepre.2008.09.011)
5. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and Metabolism 2000 85 2402-2410. (doi:10.1210/jc.85.7.2402)
6. Human Adiponectin ELISA Kit. User manual. B-Bridge International, Inc., UM-100101. Catalog K1001-1.
7. Soininen P, Kangas AJ, Wü rtz P, Tukiainen T, Tynkkynen T, Laatikainen R, Järvelin MR, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT, Savolainen MJ & Ala-Korpela M. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009 134 1781-1785. (doi:10.1039/b910205a)
8. Park JS, Cho MH, Nam JS, Yoo JS, Lee YB, Roh JM, Ahn CW, Jee SH, Cha BS, Lee EJ, Lim SK, Kim KR & Lee HC. Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. Metabolism 2010 59 677-682. (doi:10.1016/j.metabol.2009.09.013)
9. Neumeier M, Sigruener A, Eggenhofer E, Weigert J, Weiss TS, Schaeffler A, Schlitt HJ, Aslanidis C, Piso P, Langmann T, Schmitz G, Schölmerich J & Buechler C. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochemical and Biophysical Research Communications 2007 352 543-548. (doi:10.1016/j.bbrc.2006.11.058)
10. Qiao L, Zou C, van der Westhuyzen D & Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL catabolism. Diabetes 2008 57 1824-1833. (doi:10.2337/db07-0435)
11. De Vries R, Wolffenbuttel B, Sluiter W, van Tol A & Dullaart R. Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. Clinical Laboratory 2005 51 403-409. (Pubitemid 41179674)
12. Wagner A, Simon C, Oujaa M, Platat C, Schweitzer B & Arveiler D. Adiponectin is associated with lipid profile and insulin sensitivity in French adolescents. Diabetes and Metabolism 2008 34 465-471. (doi:10.1016/j.diabet. 2008.02.006)
13. Ziemke F & Mantzoros S. Adiponectin in insulin resistance: lessons from translational research. American Journal of Clinical Nutrition 2010 91 (Supplement) 258S-261S. (doi:10.3945/ajcn.2009.28449C)
14. Burns SF, Sojung L & Arslanian SA. In vivo insulin sensitivity and lipoprotein particle size and concentration in black and white children. Diabetes Care 2009 32 2087-2093. (doi:10.2337/dc09-0380)
15. Tschitter O, Fritschke A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maelker E, Häring H & Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003 52 239-243. (doi:10.2337/diabetes.52.2.239)
16. Goropashnaya A, Herron J, Sexton M, Havel P, Stanhope K, Plaetke R, Mohatt G & Boyer B. Relationships between plasma adiponectin and body fat distribution, insulin sensitivity, and plasma lipoproteins in Alaskan Yup'ik Eskimos: the CANHR Study. Metabolism 2009 58 22-29. (doi:10.1016/j.metabol.2008. 09.002)
17. Shin M & Kim O. Plasma adiponectin is associated with less atherogenic lipoprotein phenotype. Nutrition, Metabolism, and Cardiovascular Diseases, 2011. In press. (doi:10.1016/j.numecd.2010.01.014)
18. Mascarinec G, Steude JS, Franke AA & Cooney RV. Inflammatory markers in a 2-year soy intervention among premenopausal women. Journal of Inflammation 2009 7 6-8.